Dr. Janet Pope on Inappropriate ANA Testing (Choosing Wisely Study)
Dr. Jack Cush on Pseudogout
Rather good summary of talk on pathophysiology of Sjögrens from @zandbelt from #EULAR2018 https://t.co/ggHrwxwem7
— Ronan Kavanagh (@RonanTKavanagh) June 17, 2018
Nice summary of Checkpoint inhibitor immunologic side effects of relevance to rheumatologists from @zandbelt . https://t.co/V5an6ZXwtr #EULAR2018 @RheumNow
— Ronan Kavanagh (@RonanTKavanagh) June 17, 2018
Themes of #EULAR2018 PsA steals the show. Tons of choices TNFI IL12/23 IL17 and new kid IL12. Need to know what order for which pt which drug and at what dose. Exciting also for SLE with IFN more data on belimab and baricitinib trial & intalesional TNFI. @RheumNow
— Janet Pope (@Janetbirdope) June 17, 2018
Our findings indicate that patients are highly deferential to their physician’s recommendations for treatment escalation. #EULAR2018 https://t.co/R3inz7bGvg via @CreakyJoints
— Seth D. Ginsberg (@SethSaidSo) June 17, 2018
The scariest thing in Amsterdam was the mopeds whizzing along in the 'cycle lanes' (often on the pavement) at 30mph. I saw one accident, thankfully nobody seriously hurt
— Philip Gardiner (@PhilipGardiner) June 17, 2018
Fun fact. Why is cycling so pandemic in the Netherlands? 2 reasons safer than cars – kids were getting hit by motor vehicles in 1970s and shortage of gas supply at same time. Funny as now it is a problem for tourist pedestrian safety. #EULAR2018 @RheumNow
— Janet (@Janetbirdope) June 16, 2018
Top Influencers of #EULAR2018: @eular_org @RheumNow @CreakyJoints @EMEUNET @SimonRStones @philipcrobinson More 📊 https://t.co/gDfAnFeVtW
— Symplur Hashtags (@healthhashtags) June 16, 2018
Take home ideas from #EULAR2018 Saturday Pain may be centrally mediated via TNF as well as depression which could explain mood probs in chronic RA. Tapering Biologics in early PsA results in 50% flaring aka the RA story or more so don't D/C #EULAR2018 @RheumNow
— Janet (@Janetbirdope) June 16, 2018
Dr. Olga Petryna EULAR 2018 – Gout and Diabetes
Dr. Philip Robinson at EULAR18 on Gout Abstracts
Over time, this has been the most popular blog post I’ve written: Decision Fatigue in Physicians and Medicine: The Importance of Routines and Habitshttps://t.co/UQFs42djQZ pic.twitter.com/VCsTCbyOBe
— Dr. Paul Sufka (@psufka) June 16, 2018
ERA pain evolves over 1st yr and unlinks with inflammation but is related to poor sleep, disability & comorbidities. CATCH study shows 1/4 at one yr had pain >4 out of 10 and 5% had persistent widespread pain. This impacts Rx of pain different from RA OP0349 #EULAR2018 @RheumNow pic.twitter.com/E0LAcNANBb
— Janet (@Janetbirdope) June 16, 2018
Fits with my experience. And Ps A seems more forgiving of breaks from treatment. Usually works again on restart too I think.
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018
Can you D/C biologics in early PsA if using T2T strategy and pt is in remission? Results of Open label study of start and stop biologics (mostly TNFI) when in remission or LDA in early PsA. Half flared by 6 months off biologic. ?don't D/C but lower dose. #EULAR2018 @RheumNow pic.twitter.com/u3oXrZp1jx
— Janet (@Janetbirdope) June 16, 2018
Secondary #osteoporosis in systemic mastocytosis!
Prevalence ~ 30%
Beware in cascade of multiple vertebral #fractures!
👉measure serum tryptase levelvia Roux #EULAR2018#bisphosphonate pic.twitter.com/K7Ko3kTyTq
— Dr Ai Lyn Tan (@DrAiLynTan) June 16, 2018
Beautiful study by Kostine suggesting IrAEs indicate + ant- tumor effect at #eular2018 Cancer Therapies Inducing Immune-Related Adverse Events https://t.co/gkiTpo72pf via @ReachMD @HealioRheum @RheumNow
— Leonard Calabrese (@LCalabreseDO) June 16, 2018
The ACP has not helped with their ridiculous guidelines for management of Gout.
— AT (@RheummanArnaldo) June 16, 2018
Dr. Olga Petryna at EULAR 2018 – Biologics Don’t Affect Infection with Arthroplasty
#eular2018 @RheumNow ABST sat0359 ULT has positive impact on GFR w/ mean eGFR after ULT improved significantly:+2.6 [ p=0.08],+3 [p=0.04] and +2,7 [p=0.02] ml/min/1,73 m2 after average 278 days (±185) of Rx. Even better outcomes in pts at CKD IIIa level or > (eGFR >45) pic.twitter.com/ZFZxMnYUvG
— Olga Petryna (@DrPetryna) June 16, 2018
#eular18 @RheumNow ABST sat0358 Pts w/gout &T2DM have longer duration of gout (63 vs 41 mo), more likely to have tophi (37% vs 20%), joint damage (24% vs 13%) & severe gout (27% vs 13%) vs pts w/o T2DM (p<0.01). ER visits 17% vs 9% & hospitalizations 5% vs 2% p<0.001 pic.twitter.com/gN8DnAWAcO
— Olga Petryna (@DrPetryna) June 16, 2018
#eular18 @RheumNow ABST sat0356 Pegloticase leads to fast resolution of all visualised tophi in ~6.98, 7.14 and 12.02 mos for pts w/ low, medium and high BL tophus burden (p<0.0001). The rate of response inversely correlates w/total tophus burden at the beginning of Rx pic.twitter.com/fKhYwmK1OF
— Olga Petryna (@DrPetryna) June 16, 2018
#eular18 @RheumNow ABST sat0354 work productivity&presentism negatively impacted by PsA. Low disease activity and remission associated with less abstentism and improved productivity pic.twitter.com/oww2IXwaKV
— Olga Petryna (@DrPetryna) June 16, 2018
#eular18 @RheumNow ABST sat0357 only 51.7% of pts compliant with ULT ( allopurinol&uloric predominantly) after 1 year. The median time to discontinuation 248 days. Older, male & those who get their Rx from a rheumatologist are more likely to stay compliant pic.twitter.com/s1ZYzoq0p2
— Olga Petryna (@DrPetryna) June 16, 2018
Although I think we’re better at it than most (!) having that bit xtra time that isn’t available in primary care to explain and educate. It’s hard to do in 7 minutes…
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018
Can Secukinumab be safely used in AS patients with a history of uveitis? Atul Deodhar showed me that of 135 such patients in trials only 14 had flares #EULAR2018 #SAT0270
— Philip Gardiner (@PhilipGardiner) June 16, 2018
#EULAR18 @RheumNow ABST sat0171 RCTs analysis: Of the 8–11% of pts w/ANC <1000/mm3 on Sarilumab, 81/105 (RCTs) & 132/147 (OLE) were able to cont or reinitiate Rx. >3/4 pts who d/ced Rx were able to restart at 200 mg q2w or at the lower dose 150 mg pic.twitter.com/cqYcdVfjWF
— Olga Petryna (@DrPetryna) June 16, 2018
Abstract Sat 0356 showed pegloticase results in rapid resolution of tophus in bio chemical responders but is not influenced by age gender, race, BMI, tophus location. #EULAR pic.twitter.com/rUWEHEA2fZ
— Dr. John Cush (@RheumNow) June 16, 2018
29 pts with TAO thyroid associated orbitopathy due to Graves who were refractory to multiple therapies (including steroids and methotrexate) Tx with Tocilizumab. After a mean of 9months all had significant improvement. #EULAR Sat0601 pic.twitter.com/SnHfSPoW3B
— Dr. John Cush (@RheumNow) June 16, 2018
Asaiphanit. Another study (from Thailand) demonstrating poor compliance (56.6%), failure to meet SUA target (70.8%) in gout. Once again where treatment initiated by rheumatologist better adherence to treatment. #EULAR2018 @RheumNow ABST SAT0371
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018
I think I may have put on a few pounds at #EULAR2018 and my shirt could do with pressing. Ready for home. @RheumNow pic.twitter.com/b4Gpv4LOdL
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018
See one….Tweet one….Teach one. from #EULAR Abstracts pic.twitter.com/FYl0tJkeWK
— Dr. John Cush (@RheumNow) June 16, 2018
Dr. David Felson shows bone marrow lesions correlate well with pain of osteoarthritis, and may improve either treatment. from #EULAR SP0152 pic.twitter.com/Jy94IwdPYQ
— Dr. John Cush (@RheumNow) June 16, 2018
Vazquez-Mellado. Mexican patients with severe gout tend to be younger age at onset, lower educational level and socioeconomic status. Despite receiving higher allopurinol (>600mg) only 50% achieved target uric acid. #EULAR2018 @RheumNow ABST SAT0363
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018